June 1, 2017

Paul Navarre Joins Ferring Pharmaceuticals as Chief Executive Officer of Ferring Holding Inc.

PARSIPPANY, N.J., June 1, 2017 – Ferring Pharmaceuticals announced today that Paul Navarre has been appointed Chief Executive Officer of Ferring Holding Inc. In this role Mr. Navarre assumes direct responsibility for all Ferring US activities including commercial operations, clinical development and manufacturing. He succeeds Aaron Graff, who has been appointed to a global role as Executive Vice President, Chief Commercial Officer and member of the Ferring Group Executive Board.

“Ferring is a fast growing pharmaceutical company with a unique culture centered on people and patients. I am very excited to lead this organization into the next phase of its development,” said Mr. Navarre.

Paul Navarre has more than 25 years’ experience in the pharmaceuticals and consumer goods industries. He joins Ferring from Allergan, where as President of Allergan International, he managed a $3 billion specialty care business covering dermatology, ophthalmology, urology and neurosciences. During 10 years at Allergan, Mr. Navarre built a strong track record, delivering solid business results and developing multiple successful organizations.

Before joining Allergan, Mr. Navarre spent 15 years at Procter & Gamble, starting in consumer goods before moving to the company’s pharmaceuticals division. During this time, he held positions of increasing responsibility in France, the USA, Switzerland, Italy and the UK.

As CEO, Mr. Navarre will report to the board of directors of Ferring Holding Inc., chaired by Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Group.
“Paul’s extensive pharmaceutical specialty care experience and proven international leadership skills will help him take our successful US operations to the next level, pursuing our rapid expansion,” said Michel Pettigrew.


About Ferring Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company. Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics, and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

For further information:

Patrick Gorman

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000062